What you need to know:
- AstraZeneca aims for the facility to achieve zero carbon emissions and will collaborate with the Singapore government on sustainability.
- Paul Tomasic of Houlihan Lokey noted that the facility reflects AstraZeneca’s strategic focus on controlling supply chains and addressing the complex ADC manufacturing process.
On May 20, 2024, AstraZeneca announced plans for a $1.5 billion antibody-drug conjugate (ADC) facility in Singapore, backed by the Singapore Economic Development Board (EDB). This will be the company’s first full ADC production site, encompassing antibody production, drug and linker synthesis, conjugation, and final product filling. AstraZeneca has six ADCs in clinical trials and more in preclinical stages.
CEO Pascal Soriot highlighted the potential of ADCs to replace traditional chemotherapy and praised Singapore’s manufacturing excellence. EDB Chairman Png Cheong Boon welcomed the investment, emphasizing its positive impact on Singapore’s biopharmaceutical sector and job creation.
AstraZeneca aims for the facility to achieve zero carbon emissions and will collaborate with the Singapore government on sustainability. Construction starts late 2024, with full operation expected by 2029.
Paul Tomasic of Houlihan Lokey noted that the facility reflects AstraZeneca’s strategic focus on controlling supply chains and addressing the complex ADC manufacturing process. The ADC market, estimated at $10 billion and growing over 15% annually, offers significant opportunities, particularly in oncology. Recent high-profile acquisitions, like AbbVie’s purchase of ImmunoGen and Pfizer’s acquisition of Seagen, underscore the industry’s investment in ADC technology.
Do you have a story or an opinion to share? Email us on: info@falconposts.com Or follow the Falconposts on X Platform or WhatsApp for the latest updates.
